KYNAMRO Drug Patent Profile

Which patents cover Kynamro, and what generic alternatives are available?

Kynamro is a drug marketed by Kastle Theraps Llc and is included in one NDA. There is one patent protecting this drug.

This drug has forty-five patent family members in eleven countries.

The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Kynamro

Kynamro was eligible for patent challenges on January 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 29, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for KYNAMRO

International Patents:	45
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	396
Drug Prices:	Drug price information for KYNAMRO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KYNAMRO
What excipients (inactive ingredients) are in KYNAMRO?	KYNAMRO excipients list
DailyMed Link:	KYNAMRO at DailyMed

See drug prices for KYNAMRO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KYNAMRO

Constraining patent/regulatory exclusivity:

7,511,131

NDA:

203568

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for KYNAMRO

KYNAMRO is protected by one US patents.

This potential generic entry date is based on patent 7,511,131.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013		DISCN	Yes	No	7,511,131			Y

Expired US Patents for KYNAMRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	5,914,396
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	7,407,943
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	7,015,315
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	7,101,993
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013	6,166,197

EU/EMA Drug Approvals for KYNAMRO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Genzyme Europe BV	Kynamro	mipomersen sodium	EMEA/H/C/002429treatment of cholesterol and hypercholesterolaemia	Refused	no	no	no		2013-05-29

International Patents for KYNAMRO

See the table below for patents covering KYNAMRO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	267207
Japan	3553068
Japan	2795538
European Patent Office	1090025
European Patent Office	1418179

Market Dynamics and Financial Trajectory for KYNAMRO (Mipomersen): An In-Depth Analysis

Last updated: January 15, 2026

Summary

KYNAMRO (mipomersen), developed by Genzyme (a Sanofi company), is an antisense oligonucleotide targeting apolipoprotein B-100 (apoB-100), approved primarily for Homozygous Familial Hypercholesterolemia (HoFH). The drug entered the market amidst a niche patient population, facing competition from lipid-lowering therapies like PCSK9 inhibitors. This analysis explores the evolving market landscape, regulatory environment, financial performance, and future growth prospects.

---

Introduction to KYNAMRO and Its Therapeutic Context

KYNAMRO was approved by the U.S. Food and Drug Administration (FDA) in September 2013 initially for the treatment of HoFH[1]. It operates via antisense technology, reducing the production of apoB-100, a core component of LDL cholesterol.

Key Features:

Feature	Details
Mechanism of Action	Antisense oligonucleotide inhibiting apoB-100 mRNA synthesis
Indication	Homozygous Familial Hypercholesterolemia (HoFH)
Administration	Weekly subcutaneous injections
Retail Price (2023)	Approx. $13,000 per month[2]

---

Market Dynamics of KYNAMRO

1. Market Reach and Patient Population

KYNAMRO’s market is constrained by its indication and administration challenges:

• Target Demographics: Primarily adult patients with HoFH, estimated at 1,300 – 3,000 globally[3].
• Existing Conditions: Patients often have limited treatment options; lipid management is crucial to prevent cardiovascular events.
• Market Penetration: As of 2022, estimated fewer than 700 patients with access (U.S. and select markets), with many remaining untreated due to cost, administration complexity, or lack of awareness[4].

2. Competitive Landscape

Competitor	Mechanism	Market Position	Key Differentiator	Approximate Market Share (2023)
PCSK9 inhibitors (Alirocumab, Evolocumab)	Monoclonal antibodies	Broader hypercholesterolemia	Ease of use, wider label	~85% of lipid-lowering drug market[5]
Lomitapide	Microsomal triglyceride transfer protein (MTP) inhibitor	HoFH-specific	Oral administration	Niche presence, smaller market share
Bempedoic acid	ATP citrate lyase inhibitor	Statin-intolerant hyperlipidemia	Oral, convenient	Growing, but not specific for HoFH

Note: KYNAMRO’s niche remains dedicated to treatment-resistant HoFH, limiting its appeal amid broader lipid disorders.

3. Regulatory and Reimbursement Challenges

• FDA Safety Concerns: Hepatotoxicity and liver enzyme elevations have limited broader adoption.
• Pricing & Reimbursement: High cost prompts insurer scrutiny; coverage often restricted to Medicaid and specialized clinics.

4. Prescriber Adoption and Physician Perception

Physicians tend to reserve KYNAMRO for patients failing multiple therapies. Its invasive administration and adverse effect profile hinder widespread use.

---

Financial Trajectory of KYNAMRO

1. Revenue Trends

Year	Approximate Revenue (USD million)	Notes
2013	$50	Initial launch year, market debut
2014-2016	$40 – $55	Decline due to safety concerns and limited patient access
2017-2019	$25 – $35	Market stabilization, limited growth
2020-2022	<$10 million	Decline sharply, driven by competition and approval delays for newer therapies

Source: Sanofi financial reports and industry analyses[6].

2. Cost Structure and Margins

• Manufacturing Costs: High due to complex synthesis of oligonucleotides.
• Pricing Strategies: Maintains premium pricing aligned with orphan drug status but limited by payer resistance.
• Profitability: Margins modest, with ongoing R&D expenses for next-generation antisense drugs.

3. Impact of Regulatory and Clinical Developments

• Safety warnings and post-marketing restrictions have suppressed revenue.
• The global patent expiration date, initially set for 2023, has been extended due to regulatory stability and manufacturing patents.

---

Future Outlook and Growth Potential

1. Market Expansion Opportunities

Strategy	Description	Potential Impact
Regulatory Expansion	Approvals in Europe, Japan, and emerging markets	Broaden patient access
Combination Therapy	Use alongside PCSK9 inhibitors	Enhance efficacy for resistant patients
Patient Identification Improvements	Better screening for HoFH	Increase eligible patient base

2. Pipeline and Next-Generation Drugs

Sanofi has invested in antisense and RNA interference (RNAi) platforms. In addition to KYNAMRO, promising candidates include:

Candidate	Target	Status	Expected Launch	Potential Market
ARO-APOC3	Apolipoprotein C-3	Phase 2	2025	Broader hyperlipidemia
Difi-OSA	PCSK9	Preclinical	—	Adjunct therapy

3. Challenges & Risks

• Market Saturation: Dominance of PCSK9 inhibitors limits room for KYNAMRO.
• Pricing Pressure: Cost-containment by payers impacts margins.
• Safety Profile: Adverse events could hamper uptake further.
• Innovation Pace: Competition from gene therapy approaches (e.g., LPL gene therapy) could redefine the landscape.

---

Comparison with Similar Rare Disease Therapies

Therapy	Approval Year	Indication	Cost	Mode of Action	Market Size
Mipomersen (KYNAMRO)	2013	HoFH	~$156,000/year	Antisense oligonucleotide	~3,000 patients worldwide
Evolocumab (Repatha)	2015	Hyperlipidemia	~$14,100/year	Monoclonal antibody	Millions
Lomitapide (Juxtapid)	2012	HoFH	~$300,000/year	MTP inhibitor	Few hundred patients

The high price tag for KYNAMRO emphasizes its role as an orphan drug with limited economies of scale but substantial innovation value.

---

Key Regulatory and Policy Frameworks Impacting KYNAMRO

Policy Area	Impact	Key Dates & Sources
Orphan Drug Designation	Incentivizes development	U.S. Orphan Drug Act (1983)
Pricing & Reimbursement Policies	Affects access & revenue	CMS policies, insurer coverage policies (2018-2023)
FDA Safety Regulations	Post-marketing surveillance	Ongoing since approval in 2013[1]

---

Conclusion & Strategic Recommendations

Despite its innovative mechanism, KYNAMRO faces insurmountable market limitations due to its narrow indication, safety concerns, and stiff competition from scalable monoclonal antibodies. Its financial trajectory depicts a declining trend, indicating the need for strategic repositioning.

Recommendations:

• Focus on pipeline expansion with next-generation antisense and RNAi therapies targeting broader lipid disorders.
• Engage in strategic collaborations to expand geographic footprint, especially in emerging markets.
• Optimize pricing strategies aligning with payer expectations and value-based models.
• Invest in patient identification technologies to improve market penetration within the limited eligible population.
• Monitor emerging gene therapy options that could disrupt the current niche market.

---

Key Takeaways

• KYNAMRO remains a niche therapy for HoFH, with a constrained and declining market footprint.
• Competition from PCSK9 inhibitors and emerging gene therapies significantly limits growth.
• High treatment costs and administration challenges hinder widespread adoption.
• Opportunities exist in pipeline development, combination therapies, and global expansion.
• Strategic positioning must balance innovation investment with market realities to sustain long-term value.

---

FAQs

1. What is the primary indication for KYNAMRO?
KYNAMRO is approved for Homozygous Familial Hypercholesterolemia, a rare genetic disorder causing severe LDL cholesterol elevation.

2. How does KYNAMRO differ from PCSK9 inhibitors?
KYNAMRO is an antisense oligonucleotide specifically targeting apoB-100, while PCSK9 inhibitors are monoclonal antibodies enhancing LDL receptor recycling. The latter are easier to administer and have broader indications.

3. What are the main challenges facing KYNAMRO’s market?
Limited patient population, safety concerns, high costs, and stiff competition from more convenient therapies restrict its reach and revenue.

4. Are there any advances in the pipeline to replace or augment KYNAMRO?
Yes. Sanofi and other developers are progressing in antisense, siRNA, and gene therapy programs aimed at hyperlipidemia, which could expand or replace current therapies.

5. What factors will influence the future valuation of KYNAMRO?
Pipeline success, regulatory approvals in new markets, competitive dynamics, safety profile improvements, and reimbursement strategies are critical determinants.

---

References

[1] FDA. (2013). KYNAMRO Approval Letter. U.S. Food and Drug Administration.
[2] Sanofi. (2023). KYNAMRO Pricing & Access Information.
[3] National Organization for Rare Disorders. (2022). Homozygous Familial Hypercholesterolemia (HoFH).
[4] IQVIA. (2022). Market Reports on Rare Lipid Disorders.
[5] EvaluatePharma. (2023). Lipid-Lowering Agents Market Share.
[6] Sanofi Financial Reports. (2014–2022).